Latest filing published 11 Sept 2025 for MidCap Apollo Institutional Private Lending, €40.3M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Filings by Mubadala Investment Co PJSC span 4 companies, the busiest being Recursion Pharmaceuticals, Inc., MidCap Apollo Institutional Private Lending and Endeavor Group Holdings, Inc. Over a trading history stretching from 27 October 2022 to 29 July 2025, the count stands at 22 filings.
No open-market sale appears; the market trades are 19 purchases worth €62.0M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 share grant. 2025 to date brings 2 purchases and no sales.
In size, the median ticket on the buying side is €375k. None of the 18 purchases we analysed coincided with buying by another insider of the same company within 30 days.
On 11 September 2025 came the latest disclosure, an open-market purchase for €40.3M in MidCap Apollo Institutional Private Lending. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations